Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for cardiovascular endpoint reduction in older adults with hypertension
2025-520794-39-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised trial of dapagliflozin and Placebo-COD Research Private Ltd in hypertension (HTN) (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Time to first occurrence of composite cardiovascular or renal outcome. Planned start Dec 2025; status: authorised.
02
Drugs
dapagliflozinPlacebo-COD Research Private Ltd
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2025-520794-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520794-39-00.